Polyphron announced $20 million in seed financing on September 17, 2026, to build a system where AI models can test predictions against living human biology. The company argues that AI’s ability to generate biological hypotheses is advancing faster than the ability to test them, and sees human tissue as a scalable testing environment. Quiet Capital led the round. Compound, which participated, says it was among Polyphron’s first investors.